2026 BIO-Europe Spring

At BIO-Europe Spring on March 24, our colleague Souvik shared insights on contract drug development and biosafety solutions, focusing on how biopharma companies can accelerate development while maintaining high standards in viral safety, quality control, and global regulatory compliance.

As development timelines tighten and regulatory expectations continue to rise, the need for reliable, science-driven biosafety support has never been greater. The session sparked valuable discussions on how companies can reduce risk, strengthen development programs, and move toward global commercialization with greater confidence.

Thank you to everyone who joined the session and contributed to the discussion - it was a pleasure exchanging ideas with such a dynamic audience.
We look forward to continuing the conversation and connecting with more partners across biotech, pharma, CDMO, and the investment community.